They also found no changes in CCL3 and CCL4 mRNA upon BRAFi.40 These differences to our data might result from the different tumor models, additional mutations in the models (PTEN loss), the different treatment regimens and time points used for analysis of tumors. This evidence concerns the gene CCL4 and neoplasm.